je.st
news
Age, Renal Impairment and Depth of Response Analyses of the FirstTM...
2014-12-08 04:49:40| Biotech - Topix.net
Celgene Corporation today announced that results were presented from multiple post-hoc analyses of its pivotal phase III FIRSTTM trial, comparing continuous REVLIMIDA plus low-dose dexamethasone to a fixed duration of 18 cycles of Rd or 12 cycles of melphalan, prednisone and thalidomide for the treatment of newly diagnosed, transplant-ineligible multiple myeloma. The studies were presented during the 56th American Society of Hematology annual meeting.
Tags: the
age
response
depth
Category:Biotechnology and Pharmaceuticals